JP5728759B2 - Ｃ６ｏｒｆ１６７ペプチドおよびそれを含むワクチン - Google Patents

Ｃ６ｏｒｆ１６７ペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP5728759B2
JP5728759B2 JP2011542381A JP2011542381A JP5728759B2 JP 5728759 B2 JP5728759 B2 JP 5728759B2 JP 2011542381 A JP2011542381 A JP 2011542381A JP 2011542381 A JP2011542381 A JP 2011542381A JP 5728759 B2 JP5728759 B2 JP 5728759B2
Authority
JP
Japan
Prior art keywords
c6orf167
peptide
seq
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011542381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522488A (ja
JP2012522488A5 (enExample
Inventor
中村　祐輔
祐輔 中村
弥太郎 醍醐
弥太郎 醍醐
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012522488A publication Critical patent/JP2012522488A/ja
Publication of JP2012522488A5 publication Critical patent/JP2012522488A5/ja
Application granted granted Critical
Publication of JP5728759B2 publication Critical patent/JP5728759B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
JP2011542381A 2009-04-01 2010-03-31 Ｃ６ｏｒｆ１６７ペプチドおよびそれを含むワクチン Expired - Fee Related JP5728759B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21170009P 2009-04-01 2009-04-01
US61/211,700 2009-04-01
PCT/JP2010/002352 WO2010113495A1 (en) 2009-04-01 2010-03-31 C6orf167 peptides and vaccines containing the same

Publications (3)

Publication Number Publication Date
JP2012522488A JP2012522488A (ja) 2012-09-27
JP2012522488A5 JP2012522488A5 (enExample) 2013-05-16
JP5728759B2 true JP5728759B2 (ja) 2015-06-03

Family

ID=42827803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542381A Expired - Fee Related JP5728759B2 (ja) 2009-04-01 2010-03-31 Ｃ６ｏｒｆ１６７ペプチドおよびそれを含むワクチン

Country Status (14)

Country Link
US (1) US20120128705A1 (enExample)
EP (1) EP2414383A4 (enExample)
JP (1) JP5728759B2 (enExample)
KR (1) KR20120034605A (enExample)
CN (2) CN104774260A (enExample)
AU (1) AU2010231381A1 (enExample)
BR (1) BRPI1013384A2 (enExample)
CA (1) CA2757210A1 (enExample)
IL (1) IL215268A0 (enExample)
MX (1) MX2011010191A (enExample)
RU (1) RU2011144088A (enExample)
SG (2) SG174998A1 (enExample)
TW (1) TW201100090A (enExample)
WO (1) WO2010113495A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
WO2012023259A1 (en) * 2010-08-19 2012-02-23 Oncotherapy Science, Inc. C6orf167 as a target gene for cancer therapy and diagnosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521865A (ja) * 1997-10-24 2003-07-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １４８個のヒト分泌タンパク質
CN1351069A (zh) * 2000-10-26 2002-05-29 上海博德基因开发有限公司 一种新的多肽——鼠的同ampa受体相互作用的蛋白grip12.54和编码这种多肽的多核苷酸
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
DK2325306T3 (en) * 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
JP5409658B2 (ja) * 2008-03-13 2014-02-05 セレラ コーポレーション 静脈血栓症に関連した遺伝子多型、その検出方法および使用

Also Published As

Publication number Publication date
BRPI1013384A2 (pt) 2016-03-29
CN102448980A (zh) 2012-05-09
EP2414383A4 (en) 2013-07-31
CA2757210A1 (en) 2010-10-07
KR20120034605A (ko) 2012-04-12
JP2012522488A (ja) 2012-09-27
SG174998A1 (en) 2011-11-28
RU2011144088A (ru) 2013-05-10
TW201100090A (en) 2011-01-01
EP2414383A1 (en) 2012-02-08
AU2010231381A1 (en) 2011-11-03
MX2011010191A (es) 2011-11-29
SG2014011423A (en) 2014-05-29
CN102448980B (zh) 2015-04-15
IL215268A0 (en) 2011-11-30
US20120128705A1 (en) 2012-05-24
CN104774260A (zh) 2015-07-15
WO2010113495A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
JP6349560B2 (ja) Ｔｏｐｋペプチドおよびそれを含むワクチン
JP5799394B2 (ja) Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
CN102947325B (zh) Cdca5肽及包含它们的疫苗
JP5884104B2 (ja) 改変ｍｅｌｋペプチドおよびそれを含むワクチン
JP5564730B2 (ja) Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
JP2016222676A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
JP5786178B2 (ja) Ｔｔｋペプチドおよびそれを含むワクチン
JP5838482B2 (ja) Ｈｊｕｒｐペプチドおよびそれを含むワクチン
JP5816965B2 (ja) Ｅｃｔ２ペプチドおよびそれを含むワクチン
CN102448980B (zh) C6orf167肽及包含它的疫苗
JP2013540419A (ja) Ｔｔｌｌ４ペプチドおよびそれを含むワクチン
JP2013513549A (ja) Ｔｍｅｍ２２ペプチドおよびそれを含むワクチン
JP2013512659A (ja) Ｍｙｂｌ２ペプチドおよびそれを含むワクチン
JP2016502499A (ja) Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン
JP2014504146A (ja) Ｗｄｈｄ１ペプチドおよびそれを含むワクチン
JP2014500001A (ja) Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
JP2013523083A (ja) Ｃｌｕａｐ１ペプチドおよびそれを含むワクチン
HK1201542B (en) Topk peptides and vaccines including the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150317

R150 Certificate of patent or registration of utility model

Ref document number: 5728759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees